Pharmaceuticals
Eli Lilly’s obesity pill led to around 12% weight loss in closely watched late-stage trial, paving way for approval
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly on Thursday said the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in […]
Read More
Eli Lilly earnings are coming Thursday. Here’s what top analysts expect
Many on Wall Street expect that Novo Nordisk ‘s loss has been Eli Lilly ‘s gain, and this will be good news for the Zepbound maker’s second-quarter results. Novo Nordisk’s stock has cratered about 47% since the start of the year, as doubts emerged about the outlook for its GLP-1 drugs, Ozempic for diabetes and […]
Read More
Novo Nordisk doubles down on Trump-friendly sales strategy
Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024. Hollie Adams | Reuters Wegovy-maker Novo Nordisk said Wednesday that it was doubling down on direct-to-consumer sales as it contends with copycat compounders and Washington’s demands for lower domestic drug prices. Chief Financial Officer Karsten Munk Knudsen […]
Read More
Trump says pharma tariffs could eventually reach up to 250%
U.S. President Donald Trump talks to members of the press at Lehigh Valley International Airport in Allentown, Pennsylvania, U.S., August 3, 2025. Ken Cedeno | Reuters President Donald Trump told CNBC’s “Squawk Box” on Tuesday that planned tariffs on pharmaceuticals imported into the U.S. could eventually reach up to 250%, the highest rate he has […]
Read More
Pfizer hikes 2025 profit outlook on cost cuts, strong quarterly results
Exterior view of the Pfizer headquarters building on January 29, 2023 in New York City. View Press | Corbis News | Getty Images Pfizer on Tuesday hiked its full-year adjusted profit guidance on its cost cuts and strong business performance this year. The company also reported second-quarter results that topped Wall Street’s estimates for the […]
Read More
Moderna cuts high end of 2025 revenue outlook on vaccine shipment delay in U.K.
Moderna logo is seen in Warsaw, Poland on April 9, 2025. Jakub Porzycki | Nurphoto | Getty Images Moderna on Friday lowered the high end of its 2025 revenue outlook due to a delay in vaccine shipments to the U.K., but beat Wall Street’s expectations for the second quarter as it works to cut costs. […]
Read More
Trump’s drug price ultimatum sets pharma firms scrambling
Key Points A fresh ultimatum demanding “binding commitments” to lower U.S. drug prices sent pharma firms scrambling Friday. President Trump sent letters to 17 major firms outlining the steps they must take to cut costs. Healthcare stocks tumbled Friday, following broader market losses as investors digested Trump’s amended tariffs. Pharmaceutical firms are scrambling to respond […]
Read More
Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity
Mounjaro manufactured by Eli Lilly and Company packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on April 9, 2024. Nurphoto | Nurphoto | Getty Images Eli Lilly on Thursday said its blockbuster diabetes drug Mounjaro showed heart health benefits in a late-stage trial directly comparing it to the company’s […]
Read More
CVS shares pop on earnings beat and outlook, as retail pharmacy and insurance units improve
CVS Health on Thursday reported second-quarter earnings and revenue that topped estimates and raised its adjusted profit outlook, as it sees strength in its retail pharmacy business and some improvement in its insurance unit. Shares of the retail drugstore chain jumped more than 9% in premarket trading Thursday. The company now expects fiscal 2025 adjusted […]
Read More
Moderna to slash 10% of workforce as biotech cuts costs, Covid shot sales slow
The Moderna Inc. headquarters in Cambridge, Massachusetts, on March 26, 2024. Adam Glanzman | Bloomberg | Getty Images Moderna on Thursday said it plans to slash roughly 10% of its global workforce by the end of the year, as Covid shot sales continue to dwindle and the company grapples with uncertainty in the vaccine market. […]
Read More